Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms
Journal article published in 2021 by
Clémence Marcault 
,
Lin-Pierre Zhao,
Nabih Maslah ,
Emmanuelle Verger ,
Rafael Daltro de Oliveira ,
Juliette Soret-Dulphy,
Marine Cazaux,
Nicolas Gauthier ,
Blandine Roux,
Emmanuelle Clappier ,
Nathalie Parquet,
Christine Dosquet,
Delphine Réa ,
Jean-Marc Zini,
William Vainchenker
and other authors.
,
Lin-Pierre Zhao,
Nabih Maslah ,
Emmanuelle Verger ,
Rafael Daltro de Oliveira ,
Juliette Soret-Dulphy,
Marine Cazaux,
Nicolas Gauthier ,
Blandine Roux,
Emmanuelle Clappier ,
Nathalie Parquet,
Christine Dosquet,
Delphine Réa ,
Jean-Marc Zini,
William Vainchenker
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Marcault et al report the impact of NFE2 mutations on the prognosis of patients with myeloproliferative neoplasms (MPNs) in a study of over 700 patients for whom sequential next-generation sequencing was available. NFE2 mutations were reported in 9.1% of patients and predicted for increased transformation and decreased survival. Since histone deacetylase (HDAC) inhibitors decrease NFE2 levels, patients with NFE2 mutations may benefit from HDAC inhibitors.